Azitra

Azitra Inc. is a biotechnology company specializing in the development of medical dermatology products that leverage the skin microbiome. The company focuses on creating safe, effective, and easy-to-use treatments for various skin conditions. Azitra's product pipeline includes four Live Biotherapeutic Product (LBP) candidates, with one currently in clinical trials for treating cancer therapy-associated rashes. The company's technology platform offers multiple product opportunities in three main areas: direct application of commensal bacteria, pharmaceuticals based on biotherapeutic protein delivery via proprietary bacteria strains, and the discovery and development of novel bioactive compounds such as antimicrobials and other therapeutics. Azitra primarily serves the medical dermatology market, targeting conditions like cancer therapy-associated rashes and orphan skin diseases. The company generates revenue through the development and commercialization of its proprietary dermatology products.

Keywords: medical dermatology, skin microbiome, biotherapeutics, cancer therapy rashes, orphan skin diseases, commensal bacteria, antimicrobials, bioactive compounds, proprietary bacteria strains, biotechnology.